Actively Recruiting
Microbiota Mediated Flavonoid Metabolites for Cognitive Health
Led by University of Ulster · Updated on 2025-11-24
100
Participants Needed
1
Research Sites
109 weeks
Total Duration
On this page
Sponsors
U
University of Ulster
Lead Sponsor
U
University of Parma
Collaborating Sponsor
AI-Summary
What this Trial Is About
Globally, populations are ageing increasing the prevalence of Alzheimer's disease (AD), due to lack of effective treatments. The traditional Mediterranean diet, rich in fibre and polyphenols (PPs) can help prevent or delay cognitive dysfunction and preserve healthy brain structure and function. Cognitive decline is inversely associated with higher PP intakes (\>421mg/day) i.e., total flavonoids, flavan-3-ols and flavonoid oligomers. The positive brain effects of flavonoid intake are likely mediated in part by gut microbial PP metabolites, consistent with the emerging role of the brain-gut microbiome (BGM) system in neurodegeneration. Our preliminary data indicate that circulating phenyl-γ-valerolactones (PVL), neuroprotective compounds exclusively produced by gut microbiota from flavan-3-ol rich foods18 are associated with delaying cognitive dysfunction. Intake of PPs change gut microbial composition and function, altering the physiology of the host's secondary bile acid (BA) pool through modulation of bacterial 7α-dehydroxylation of de-conjugated primary BAs into secondary BAs. This is noteworthy as 7α-dehydroxylation of BAs does not happen in the brain and because gut microbial BA metabolites have regulatory and signalling functions in the brain. The ratio between certain primary and secondary BAs is also dysregulated in AD with significantly lower serum concentrations of cholic acid (a primary BA) and increased levels of deoxycholic acid (a bacterially produced secondary BA). The increased ratio of cholic acid to deoxycholic acid is correlated with cognitive decline. Increased levels of tyrosine, tryptophan, purine, and tocopherol have also been identified in postmortem AD brains. However, specific pathways and mechanisms underlying these associations are unclear. In this multi-PI application by leaders in the field of BGM interactions, we leverage the collectively (NIH, HSC, SFI) funded Tripartite US-Ireland R\&D Partnership Program to determine the mechanisms involved in PP intake on maintaining healthier cognitive and brain function, as mediated by gut microbiota metabolites of PP and BAs in 50+ year old elderly with enhanced AD risk.
CONDITIONS
Official Title
Microbiota Mediated Flavonoid Metabolites for Cognitive Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 50 years of age or older
- Body Mass Index (BMI) of 25 kg/m2 or higher
- Increased risk of Alzheimer's disease defined by family history with a first-degree relative
- Habitual consumption of a typical Western diet high in animal products, refined carbohydrates, and processed foods
- Willing and able to follow the study protocol and provide written informed consent
You will not qualify if you...
- Cognitive impairment at recruitment as measured by Mini Mental Status Exam (score below 25), Clinical Dementia Rating (score above 0), or Everyday Cognition Scale-12 (score above 1.36)
- Pre-existing psychosis or psychiatric conditions
- Currently receiving dementia treatment
- History of substance abuse or cerebrovascular events
- Heavy tobacco use (more than half a pack per day)
- Known or suspected allergy or intolerance to study product components
- Use of probiotics or antibiotics within the past month
- Medication changes within the last 3 months
- Frailty, malnutrition, or food allergies/intolerances requiring special diets
- Following specific diets such as vegetarian or vegan
- Weight over 400 pounds (due to MRI table limits)
- Pregnant, breastfeeding, postpartum less than 6 months, or unwilling to use birth control during the study
- Unable to safely undergo MRI (e.g., claustrophobia, pacemakers, neurostimulators, metallic foreign bodies)
- Chronic pain
- Any condition that may compromise safety or data quality as judged by the investigator
- Psychological or language barriers preventing informed consent
- Under legal protection or deprived of rights by judicial decision
- Participation in other biomedical studies currently or within 3 months before this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ulster University, Human Intervention Studies Unit
Coleraine, United Kingdom, BT52 1SA
Actively Recruiting
Research Team
C
Chris Gill, PhD
CONTACT
A
Aoife Caffrey, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here